Document Type

Article

Publication Date

6-26-2024

Comments

This article is the author's final published version in Transplantation Direct, Volume 10, Issue 7, June 2024, Pages e1663.

The published version is available at https://doi.org/10.1097/TXD.0000000000001663.

Copyright © 2024 The Author(s)

Abstract

BACKGROUND: Enhanced recovery after surgery (ERAS) pathways represent a comprehensive approach to optimizing perioperative management and reducing hospital stay and cost. In living donor kidney transplantation, key impediments to postoperative discharge include pain, and opioid associated complications such as nausea, vomiting, and the return of gastrointestinal function.

METHODS: In this randomized controlled trial, living kidney transplantation donors were assigned to either the ERAS or control group. The ERAS group patients received 15 preoperative, 17 intraoperative, 19 postoperative element intervention. The control group received standard care. The ERAS group received a multimodal opioid sparing pain management including an intraoperative transverse abdominis plane block. Our primary outcome measure was postoperative opioid consumption. The secondary outcome measures were postoperative pain scores, first oral intake, and hospital length of stay.

RESULTS: There were no significant differences in demographics between the 2 groups. The ERAS group had a statistically significant reduction in total postoperative opioid consumption calculated in intravenous morphine equivalents (24.2 ± 20.2 versus 71 ± 39.5 mg,

CONCLUSIONS: The ERAS group experienced superior postoperative analgesia and a shorter length of hospital stay compared with controls.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Additional Files
Supplementary Materials.pdf (196 kB)

PubMed ID

38953038

Language

English

Download

Share

COinS